Retatrutide: what it is and where the research stands

Retatrutide is an investigational synthetic peptide developed by Eli Lilly, known as LY3437943 in the research literature. It is a triple receptor agonist — a single molecule that binds to and activates three different receptors involved in metabolic regulation: the GLP-1 receptor, the GIP receptor, and the glucagon receptor. Retatrutide is currently in advanced clinical development but is not yet an approved medicine in the UK, EU, or US.

The peer-reviewed Phase 2 trial published in the New England Journal of Medicine in 2023 (Jastreboff et al.) reported mean weight change of −24.2% at the 12 mg dose after 48 weeks in adults with obesity, compared with −2.1% for placebo. At the highest dose, 100% of participants achieved ≥5% weight reduction and 26% achieved ≥30%. A separate Phase 2a study in Nature Medicine in 2024 reported liver-fat reduction of −86.0% at 48 weeks in participants with metabolic dysfunction-associated steatotic liver disease. All findings are described as observed in trial participants — Retatrutide is investigational and not approved for use.

Retatrutide is not authorised as a medicine by the MHRA in the UK, the EMA in the EU, or the FDA in the US. It cannot lawfully be sold or supplied for human use. Research-use supply for laboratory purposes only is a separate legal category and is what any UK supplier of Retatrutide is offering. Any seller presenting Retatrutide as an approved therapy is misrepresenting it.

All three are peptide molecules that act on incretin-related receptors, but they differ in the number of receptors they target. Semaglutide is a single receptor agonist, acting on the GLP-1 receptor. Tirzepatide is a dual agonist, acting on GLP-1 and GIP receptors. Retatrutide is a triple agonist, adding the glucagon receptor as a third target. In pharmacological research, this multi-receptor engagement is why Retatrutide has been of interest — the metabolic effects observed in Phase 2 trials have been more pronounced than those reported for single or dual agonists at comparable stages of development.

A freeze-dried peptide pen contains the compound in its dry, powdered form. The peptide is dissolved only when the buyer reconstitutes it with bacteriostatic water. This differs from a pre-filled pen, where the peptide has been dissolved at the point of manufacture and remains in solution through shipping, customs, warehousing, and delivery. Since peptides are chemically fragile once in solution — hydrolysis and oxidation begin immediately and continue for as long as the peptide stays dissolved — freeze-dried format preserves stability. Full detail on freeze-dried vs pre-filled.

The industry benchmark for research-grade peptides is 98% or higher purity by High-Performance Liquid Chromatography (HPLC). Identity should be independently confirmed by mass spectrometry — a molecular-weight measurement that verifies the compound is what the label claims. A COA that reports purity without an identity check is only telling half the story. See how to read a peptide Certificate of Analysis for the full breakdown.

Every research compound sold by a serious supplier should be tested by a named, independent third-party laboratory with no commercial interest in the result. Janoshik Analytical is widely used across the research peptide sector. Optigenix Retatrutide 40mg is independently tested and the Certificate of Analysis is published per batch in the COA Library.

The 40mg refers to the total mass of Retatrutide contained in the freeze-dried peptide pen. This is a quantity descriptor, not a dosing instruction. Research use of any investigational compound is conducted per an experimental protocol designed by the researcher; the label quantity is simply for identification and stock management.

Retatrutide has not been individually named on the World Anti-Doping Agency (WADA) Prohibited List at the time of writing, but its class — non-approved substances (Section S0) and peptide hormones — falls squarely within categories WADA already prohibits in competitive sport. Any athlete considering research compounds should verify current WADA rules directly and consult their national anti-doping organisation before any decision.

The main Phase 2 papers are: Jastreboff AM et al., N Engl J Med 2023 (PMID 37366315, weight and metabolic outcomes in obesity); Sanyal AJ et al., Nat Med 2024 (PMC PMC11271400, liver-fat outcomes in MASLD). Both are freely accessible and provide the full trial design, dose groups, endpoints, and safety data.